ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?
Executive Summary
CDER Director Woodcock says it may not be necessary for the ANDA first-cycle approval rate to approach that for NDAs, but lowering the number of cycles to two would be desirable.
You may also be interested in...
Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
Office of Generic Drugs Director Kathleen Uhl calls a two-cycle approval timeline a realistic expectation for ANDA approval, but would not say that most ANDAs will fall into the paradigm.
Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
Office of Generic Drugs Director Kathleen Uhl calls a two-cycle approval timeline a realistic expectation for ANDA approval, but would not say that most ANDAs will fall into the paradigm.
US FDA Wants To Predict ANDA Complete Response Responses
Generic industry, FDA discuss potential ways to increase transparency so agency can better estimate when – and even whether – an ANDA receiving a complete response will be returned.